These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 28408527)

  • 21. Targeted alpha-particle therapy of microscopic disease: Providing a further rationale for clinical investigation.
    Zalutsky MR
    J Nucl Med; 2006 Aug; 47(8):1238-40. PubMed ID: 16882999
    [No Abstract]   [Full Text] [Related]  

  • 22. Can α-radioimmunotherapy increase efficacy for the systemic control of cancer?
    Allen BJ
    Immunotherapy; 2011 Apr; 3(4):455-8. PubMed ID: 21463184
    [No Abstract]   [Full Text] [Related]  

  • 23. The magic-bullet: moving the concept towards reality – part II.
    Elgqvist J
    Curr Radiopharm; 2011 Oct; 4(4):281-2. PubMed ID: 22202150
    [No Abstract]   [Full Text] [Related]  

  • 24. Targeted Radiotherapy with Alpha-Particle Emitting Radionuclides Seminar, November 18, 2004, Cracow, Poland.
    Zalutsky MR; Petelenz B
    Nucl Med Rev Cent East Eur; 2004; 7(2):195. PubMed ID: 15968616
    [No Abstract]   [Full Text] [Related]  

  • 25. [Principles, modalities and indications of the administration of Radium in cancers, focus on metastatic prostate cancer: State of arts].
    Bertolaso P; Leroy L; Gross-Goupil M; Aupee O; Ravaud A; Roubaud G; Cazeau AL; Le Moulec S
    Bull Cancer; 2017 Sep; 104(9):762-770. PubMed ID: 28797482
    [TBL] [Abstract][Full Text] [Related]  

  • 26. α- Versus β-Emitting Radionuclides for Pretargeted Radioimmunotherapy of Carcinoembryonic Antigen-Expressing Human Colon Cancer Xenografts.
    Heskamp S; Hernandez R; Molkenboer-Kuenen JDM; Essler M; Bruchertseifer F; Morgenstern A; Steenbergen EJ; Cai W; Seidl C; McBride WJ; Goldenberg DM; Boerman OC
    J Nucl Med; 2017 Jun; 58(6):926-933. PubMed ID: 28232604
    [TBL] [Abstract][Full Text] [Related]  

  • 27. First in-beam PET measurement of beta+ radioactivity induced by hard photon beams.
    Kluge T; Möckel D; Pawelke J; Enghardt W
    Phys Med Biol; 2007 Oct; 52(20):N467-73. PubMed ID: 17921570
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Radioimmunotherapy with alpha-particle emitting radionuclides.
    Zalutsky MR; Pozzi OR
    Q J Nucl Med Mol Imaging; 2004 Dec; 48(4):289-96. PubMed ID: 15640792
    [TBL] [Abstract][Full Text] [Related]  

  • 29. RBE of ion beams in hypofractionated radiotherapy (SBRT).
    Friedrich T; Scholz U; Durante M; Scholz M
    Phys Med; 2014 Jul; 30(5):588-91. PubMed ID: 24857333
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Astatine-211 imaging by a Compton camera for targeted radiotherapy.
    Nagao Y; Yamaguchi M; Watanabe S; Ishioka NS; Kawachi N; Watabe H
    Appl Radiat Isot; 2018 Sep; 139():238-243. PubMed ID: 29864741
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Alpha-Radioimmunotherapy: principle and relevance in anti-tumor immunity].
    Ménager J; Gorin JB; Fichou N; Gouard S; Morgenstern A; Bruchertseifer F; Davodeau F; Kraeber-Bodéré F; Chérel M; Gaschet J; Guilloux Y
    Med Sci (Paris); 2016 Apr; 32(4):362-9. PubMed ID: 27137693
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumor control probability for tumor therapy with beta radionuclide interstitial injection.
    Chen Y; Geng J; Tian J; He Y; Chen S
    Biomed Mater Eng; 2004; 14(3):333-5. PubMed ID: 15299245
    [No Abstract]   [Full Text] [Related]  

  • 33. Somatostatin-receptor-targeted alpha-emitting 213Bi is therapeutically more effective than beta(-)-emitting 177Lu in human pancreatic adenocarcinoma cells.
    Nayak TK; Norenberg JP; Anderson TL; Prossnitz ER; Stabin MG; Atcher RW
    Nucl Med Biol; 2007 Feb; 34(2):185-93. PubMed ID: 17307126
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Radioimmunotherapy for acute leukemia.
    Burke JM; Jurcic JG; Scheinberg DA
    Cancer Control; 2002; 9(2):106-13. PubMed ID: 11965231
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of two dedicated 'in beam' PET systems via simultaneous imaging of (12)C-induced beta(+)-activity.
    Attanasi F; Belcari N; Del Guerra A; Enghardt W; Moehrs S; Parodi K; Rosso V; Vecchio S
    Phys Med Biol; 2009 Jan; 54(2):N29-35. PubMed ID: 19088389
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Autoradiography imaging in targeted alpha therapy with Timepix detector.
    A L Darwish R; Staudacher AH; Bezak E; Brown MP
    Comput Math Methods Med; 2015; 2015():612580. PubMed ID: 25688285
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evolution of treatment options for patients with CRPC and bone metastases: bone-targeted agents that go beyond palliation of symptoms to improve overall survival.
    Rove KO; Crawford ED
    Oncology (Williston Park); 2011 Dec; 25(14):1362-70, 1375-81, 1387. PubMed ID: 22329188
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Beta decay in science and medicine.
    Welsh JS
    Am J Clin Oncol; 2007 Aug; 30(4):437-9. PubMed ID: 17762446
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Beta therapy of vulvar leukoplakia].
    Vlakhov N; Parusheva D; Kovachev A; Boiadzhiev P
    Med Radiol (Mosk); 1990 Feb; 35(2):53. PubMed ID: 2314207
    [No Abstract]   [Full Text] [Related]  

  • 40. Relative biologic effects of low-dose-rate alpha-emitting 227Th-rituximab and beta-emitting 90Y-tiuexetan-ibritumomab versus external beam X-radiation.
    Dahle J; Bruland OS; Larsen RH
    Int J Radiat Oncol Biol Phys; 2008 Sep; 72(1):186-92. PubMed ID: 18722269
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.